AUSTIN, Texas, April 1, 2021
/PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a
clinical-stage biotechnology company developing a new generation of
human enzyme therapeutics to benefit people with rare metabolic
diseases, today announced it will participate in two virtual
investor conferences in April 2021.
Conference Details
Conference Name: 2021 Virtual Wells Fargo Biotech Corporate
Access Day
Conference Date: Tuesday, April 6 and Thursday, April 8
Participants: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer and Michael C. Hanley, Aeglea's chief commercial
officer
Conference Name: 20th Annual Needham Virtual
Healthcare Conference
Conference Date: Monday, April 12
through Thursday, April 15
Presentation Date and Time: Tuesday, April
13 at 11:00 am ET
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea's
president and chief executive officer
Webcast: https://ir.aeglea.com/events-and-presentations/
To access the live and archived webcast, visit the Events &
Presentations section of the Company's website. Please connect to
the website at least 15 minutes prior to the presentation to allow
for any software download that may be necessary. A replay of the
webcast will be available through the Company's website for 30 days
thereafter.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company
redefining the potential of human enzyme therapeutics to benefit
people with rare metabolic diseases with limited treatment options.
Aeglea's lead product candidate, pegzilarginase, is in a pivotal
Phase 3 trial for the treatment of Arginase 1 Deficiency and has
received both Rare Pediatric Disease and Breakthrough Therapy
Designation. The Company initiated a Phase 1/2 clinical trial of
AGLE-177 for the treatment of Homocystinuria in 2020. AGLE-177 has
also been granted Rare Pediatric Disease Designation. Aeglea has an
active discovery platform focused on engineering small changes in
human enzymes to have big impact on the lives of patients and their
families. For more information, please visit http://aeglea.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aeglea-biotherapeutics-to-participate-in-two-virtual-investor-conferences-in-april-2021-301261051.html
SOURCE Aeglea BioTherapeutics, Inc.